You are browsing the Hong Kong website, Regulated by Hong Kong SFC (CE number: BJA907). Investment is risky and you must be cautious when entering the market.
魯信創投(600783.SH):參股項目Intarcia正式委託第三方實施資產處置和清算程序
格隆匯 12-27 18:10
格隆匯 12 月 27日丨魯信創投(600783.SH)公佈,公司接全資子公司山東省高新技術創業投資有限公司(“山東高新投”)通知,其全資子公司齊魯投資有限公司(“齊魯投資”)通過開曼SPV特殊目的公司DRAGON RIDER LIMITED (“開曼SPV”)投資項目美國公司Intarcia Therapeutics Inc. (“Intarcia”)經營出現重大變化,擬調低對Intarcia的估值。

Intarcia是一家致力於慢性病藥物研發的生物製藥企業,公司在研產品ITCA650是一種創新治療二型糖尿病的年製劑給藥裝置,今年第二次向美國食品及藥物管理局(“FDA”)提交新藥申請,但被拒絕。Intarcia目前仍在向FDA申請上訴,但其已無必要的資金及資源繼續維持運營。公司於近日收到Intarcia通知,其正式委託第三方實施資產處置和清算程序。

公吿顯示,2016年7月,公司九屆二次董事會審議通過了《關於山東省高新技術創業投資有限公司對齊魯投資有限公司進行增資暨參與投資美國公司Intarcia Therapeutics Inc.的議案》。公司全資子公司山東高新投通過開曼SPV參與了Intarcia的EE輪融資,Intarcia當時核心產品ITCA650已完成三期臨牀試驗,投前估值35億美元,公司總投資額3000萬美元,持有Intarcia 50萬股優先股。

2020年2月,公司十屆十次董事會審議通過了《關於全資子公司投資美國公司Intarcia Therapeutics Inc.的議案》。公司全資子公司山東高新投通過開曼SPV參與了Intarcia的可轉債融資,總投資額220.75萬美元。

公司對所持有Intarcia優先股、可轉債按照新金融工具準則作為以公允價值計量且其變動計入當期損益的金融資產,列報於其他非流動金融資產。對於該類資產公司按年度進行公允價值估值。基於謹慎性原則,本次擬在2020年度期末將其估值下調至0,預計產生公允價值變動損失1.4億元人民幣公司項目組將持續關注後續進展,盡最大可能爭取我方權益,減少損失。

同時,針對境外早期研發類項目存在的研發風險及市場前景不達預期風險,公司未來境外業務的開展,將在佈局領域及投資金額上做進一步調整,分散投資風險。

Follow us
Find us on Facebook, Twitter , Instagram, and YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!
Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.
uSMART
Wealth Growth Made Easy
Open Account